Every 8-K that Ovid Therapeutics Inc. (OVID) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OVID and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OVID filings page.
Ovid Therapeutics Inc. reported second quarter 2026 results and extensive pipeline progress in neurology and psychiatry. The company is advancing OV4071, described as the first oral direct KCC2 activator, through an ongoing Phase 1 study in healthy volunteers, with data expected to support a Phase 2 schizophrenia proof‑of‑concept study in 2027 and a ketamine challenge study planned for the second half of 2026.
Ovid also initiated multiple Phase 2 and proof‑of‑concept studies for OV329, a next‑generation GABA‑AT inhibitor, across treatment‑resistant focal onset seizures, tuberous sclerosis complex–associated seizures and infantile spasms, with a global randomized FOS study targeting completion in the second half of 2027 and a photosensitivity study expecting results near year‑end 2026. A newly formed Perceptive Advisors–backed company acquired global rights to soticlestat, leaving Ovid eligible for up to $294.5 million in potential milestone payments plus low‑ to mid‑single digit royalties.
Liquidity strengthened meaningfully: cash, cash equivalents and marketable securities were $169.8 million as of June 30, 2026, and Ovid states this supports operations into 2029, helped by approximately $53.9 million of warrant‑exercise proceeds in April 2026. For the quarter, revenue was $0.7 million versus $6.3 million a year earlier, while net loss widened to $15.0 million from $4.7 million, driven by higher research and development and general and administrative expenses as clinical activity expanded.
Ovid Therapeutics Inc. is changing its finance leadership while keeping continuity. The company and Jeffrey Rona, its Chief Business and Financial Officer and principal financial and accounting officer, mutually agreed to his transition from these roles effective July 6, 2026. The board appointed Charles Carter, previously Senior Vice President of Finance and Financial Planning, as Chief Financial Officer, principal financial officer, principal accounting officer and secretary from the same date. The company states that Rona’s departure is not due to any disagreement over accounting, controls, operations or policies.
Carter will receive a $460,000 annual base salary, a target bonus equal to 35% of salary, and 50,000 restricted stock units vesting in two equal annual installments starting July 6, 2027, plus an additional cash bonus opportunity of $75,000. Rona’s separation agreement provides 12 months of base salary, a prorated 2026 bonus, up to 12 months of COBRA benefits, and post-termination non-solicitation covenants. He will serve as a consultant through December 31, 2027, earning a one-time cash retainer and hourly consulting fees, with his existing equity awards continuing to vest during the consulting period.
Ovid Therapeutics Inc. reported the results of its annual stockholder meeting held on June 10, 2026. Of 173,037,131 common shares outstanding as of April 15, 2026, 130,958,928 shares, or 75.7%, were represented, providing a valid quorum.
Stockholders elected Jeremy M. Levin to a three-year term on the board of directors, with 87,219,707 votes for, 8,528,008 withheld, and 35,211,213 broker non-votes. They also approved, on an advisory basis, the compensation of named executive officers.
In addition, stockholders ratified the selection of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 130,845,667 votes for, 32,505 against, and 80,756 abstentions.
Ovid Therapeutics Inc. appointed Anna Greka, M.D., Ph.D. to its Board of Directors as a Class III director, effective June 15, 2026. Her term will run until the company’s 2029 annual meeting of stockholders, at which point she would be eligible for re-election.
With her appointment, the Board will expand to seven directors. Dr. Greka will serve on the Compensation Committee and the Science and Technology Committee. She is a Professor of Medicine at Harvard Medical School and holds multiple leadership roles at the Broad Institute, bringing deep scientific and biotech advisory experience.
As a non-employee director, Dr. Greka will receive compensation under Ovid’s standard non-employee director compensation policy and has entered into the company’s standard indemnification agreement. The company states there are no related-party relationships or arrangements requiring disclosure under Regulation S-K Item 404(a).
Ovid Therapeutics reported first quarter 2026 results and detailed progress across its neurology pipeline. The company ended March 31, 2026 with cash, cash equivalents and marketable securities of $165.6 million, not including an additional $27.3 million from April warrant exercises, and expects this cash to fund operations into 2029.
Ovid raised $60.0 million in gross proceeds from a March 2026 PIPE financing and received $53.9 million in gross proceeds from the full exercise of Series A warrants issued in an October 2025 private placement. In the quarter, research and development spending rose as OV329 and OV4071 advanced, leading to a net loss of $17.0 million, or $0.12 per share.
Clinically, OV329 showed favorable safety, tolerability and pharmacokinetics up to 9 mg, supporting planned Phase 2 studies in treatment-resistant focal onset seizures, with additional programs planned in tuberous sclerosis complex seizures and infantile spasms. Ovid also dosed the first healthy volunteer in a Phase 1 study of OV4071, its first oral KCC2 direct activator, and outlined broader KCC2 portfolio plans in multiple CNS disorders.
Ovid Therapeutics Inc. reported that its Series A Warrants issued in an October 2025 private placement expired on April 17, 2026. Holders elected to exercise warrants into 33,597,860 common shares at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per warrant.
These exercises covered most of the 38,481,325 common shares underlying the Series A Warrants and generated approximately $53.9 million in gross cash proceeds for the company.
Ovid Therapeutics entered a private placement financing, agreeing to sell 19,154,321 common shares at $2.01 and pre-funded warrants for up to 10,701,710 shares at $2.009 each, for expected gross proceeds of $60.0 million before fees. The company signed a registration rights agreement to register these securities for resale shortly after closing.
Ovid reported favorable 7 mg Phase 1 data for OV329 and plans a Phase 2 trial in treatment-resistant focal onset seizures plus new studies in tuberous sclerosis complex seizures and infantile spasms. OV4071 received clearance to begin Phase 1 in Australia, triggering a 30-day exercise window for Series A warrants that could add up to $53.9 million in gross proceeds.
As of December 31, 2025, Ovid held $90.4 million in cash, cash equivalents and marketable securities and reported 2025 revenue of $7.3 million, total operating expenses of $49.7 million and a net loss of $17.4 million, while fourth quarter 2025 net income was $9.7 million driven mainly by a fair value gain on an equity investment.
Ovid Therapeutics Inc. reported that it has released new information on its experimental therapy OV350. The company issued a press release announcing results from its Phase 1 study of OV350, an early-stage clinical trial that primarily evaluates safety, dosing, and how the drug behaves in the body. The press release, dated December 18, 2025, is attached as an exhibit to this report for investors and the public to review.
Ovid Therapeutics (OVID) announced a leadership succession. The Board appointed Margaret “Meg” Alexander as Chief Executive Officer and a Class II director, effective January 1, 2026. She will remain President and step down as COO. Dr. Jeremy M. Levin, CEO since 2015, will transition to Executive Chairman on the same date.
Alexander’s amended employment agreement provides a $625,000 base salary, a target bonus of 55% of salary, and reimbursement of up to $35,000 in legal fees. Following her appointment, she will receive a stock option to purchase 890,000 shares, with a 10-year term, a vesting commencement date of January 1, 2026, 25% vesting after one year, and the remainder monthly over 36 months. Severance includes 12 months of base salary and up to 12 months of health premium cash payments; upon a change in control, severance extends to 18 months, includes a bonus component, health premiums for up to 18 months, and full vesting of unvested equity.
Levin’s amended agreement (effective January 1, 2026) includes a $430,000 base salary, a 50% target bonus, and up to $35,000 in legal fee reimbursement, with a three‑year term. The company also furnished a press release with business updates and Q3 2025 results as Exhibit 99.1.
Ovid Therapeutics filed an Form 8-K disclosing a material event and attaching key transaction documents. The filing includes a Securities Purchase Agreement dated October 2, 2025 between Ovid and certain investors, a Certificate of Designation for Series B Convertible Preferred Stock, forms of Series A, Series B and Pre-Funded warrants, a Registration Rights Agreement, and a Press Release dated October 3, 2025. The cover page interactive XBRL is embedded, and the filing is signed by Jeffrey Rona, Chief Business and Financial Officer. The document list indicates a financing-related transaction with registration and governance documents filed as exhibits; specific economic terms, amounts, and closing confirmation are not provided in the text supplied.
Ovid Therapeutics Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. Nasdaq formally notified the company that it now meets Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, and that the compliance matter is closed.
This means Ovid’s common stock, listed on the Nasdaq Stock Market under the symbol OVID, is no longer at risk from this specific deficiency notice, helping preserve its current exchange listing status.
Ovid Therapeutics reported that it furnished a press release with business updates and its second quarter 2025 financial results as Exhibit 99.1. The Company disclosed it had not regained compliance with Nasdaq's minimum $1.00 closing bid requirement after the initial cure period and therefore will transfer its common stock to the Nasdaq Capital Market where it will continue trading under the symbol OVID.
The Nasdaq approved the transfer and granted the Company an additional 180-calendar-day compliance period through February 9, 2026 to regain the minimum bid price. The Company said it will monitor the closing bid price and may pursue options to regain compliance, including a reverse stock split, and noted that failure to regain compliance could lead to delisting with the right to appeal.
Ovid Therapeutics (NASDAQ:OVID) has amended its Exclusive Patent License Agreement with Immedica Pharma AB through Amendment No. 1, effective June 23, 2025. The key modification involves Immedica purchasing ongoing royalty obligations for $7.0 million in cash, payable within 10 business days. The original agreement granted Marinus (now an Immedica subsidiary) exclusive rights to ganaxolone for CDKL5 deficiency disorder treatment in the US and Europe. The amendment also provides Immedica with additional patent prosecution rights and anticipates a second amendment within six months to expand territory coverage and rights to other necessary patents.